NCT03924635View on ClinicalTrials.gov

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 16, 2022

Study Completion Date

December 16, 2022

Conditions
Airway InflammationAsthma
Interventions
COMBINATION_PRODUCT

SYMBICORT and salbutamol

SYMBICORT will be given in a TURBOHALER. Salbutamol will be given in a pressurised metered dose inhaler.

Trial Locations (6)

BD9 6RJ

Research Site, Bradford

DD1 9SY

Research Site, Dundee

NG5 1PB

Research Site, Nottingham

Unknown

Research Site, Oxford

WD18 0HB

Research Site, Watford

ML2 0DP

Research Site, Wishaw

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY